Mississauga, ON – May 1, 2017 – Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc., announced today that Health Canada has recently approved Cerdelga^TM (eliglustat capsules), the only first-line oral therapy indicated for the treatment of adult patients with Gaucher Disease Type 1.¹ A rare genetic metabolic condition that causes fats to build up in certain parts of the body, Gaucher Disease Type 1 is progressive and may become life-threatening if symptoms are left untreated.^2,3 Patients who are specific enzyme metabolisers, as detected by a simple test, will be eligible for Cerdelga treatment.¹